Earnings and Growth Analysis : Boston Omaha (NASDAQ:BOMN)

Earnings results for Boston Omaha (NASDAQ:BOMN)

Boston Omaha Corporation is estimated to report earnings on 03/12/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $0.18.

Analyst Opinion on Boston Omaha (NASDAQ:BOMN)

1 Wall Street analysts have issued ratings and price targets for Boston Omaha in the last 12 months. Their average twelve-month price target is $21.00, predicting that the stock has a possible downside of 52.09%. The high price target for BOMN is $21.00 and the low price target for BOMN is $21.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Boston Omaha has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $21.00, Boston Omaha has a forecasted downside of 52.1% from its current price of $43.83. Boston Omaha has received no research coverage in the past 90 days.

Dividend Strength: Boston Omaha (NASDAQ:BOMN)

Boston Omaha does not currently pay a dividend. Boston Omaha does not have a long track record of dividend growth.

Insiders buying/selling: Boston Omaha (NASDAQ:BOMN)

In the past three months, Inari Medical insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,166,549.00 in company stock. Only 17.77% of the stock of Inari Medical is held by institutions.

Earnings and Valuation of Boston Omaha (NASDAQ:BOMN

Earnings for Inari Medical are expected to decrease in the coming year, from $0.15 to ($0.02) per share.

More latest stories: here